{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:22:34Z","timestamp":1783038154215,"version":"3.54.6"},"reference-count":31,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We conducted this study to determine the feasibility and safety of cladribine followed by rituximab in patients with hairy cell leukemia including the vari-ant form (HCLv). Cladribine 5.6 mg\/m2 given IV over 2 hours daily for 5 days was followed \u223c 1 month later with rituximab 375 mg\/m2 IV weekly for 8 weeks. Responses were recorded and BM minimal residual disease (MRD) was evaluated after the completion of rituximab. Thirty-six patients have been treated including 5 with HCLv. Median age was 57 years (range, 37-89). All patients (100%) have achieved complete response (CR), defined as presence of no hairy cells in BM and blood with normalization of counts (absolute neutrophil count [ANC]&gt; 1.5 \u00d7 109\/L, hemoglobin [Hgb] &gt; 12.0 g\/dL, platelets [PLT] &gt; 100 \u00d7 109\/L), as well as resolution of splenomegaly. There were no grade 3 or 4 nonhematologic adverse events directly related to the treatment. Only 1 patient (with HCLv) has relapsed; median CR duration has not been reached (range,1+-63+ months). Three patients with HCLv died including 1 with relapsed disease and 2 from unrelated malignancies. Median survival duration has not been reached (range, 2+-64+ months). Treatment with clad-ribine followed by rituximab is effective tk;4and may increase CR rate. This study was registered at www.clinicaltrials.gov as NCT00412594.<\/jats:p>","DOI":"10.1182\/blood-2011-04-351502","type":"journal-article","created":{"date-parts":[[2011,8,6]],"date-time":"2011-08-06T03:55:36Z","timestamp":1312602936000},"page":"3818-3823","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":103,"title":["Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia"],"prefix":"10.1182","volume":"118","author":[{"given":"Farhad","family":"Ravandi","sequence":"first","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Koller","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramoda","family":"Challagundla","sequence":"additional","affiliation":[{"name":"Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergernne","family":"York","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Brandt","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajyalakshmi","family":"Luthra","sequence":"additional","affiliation":[{"name":"Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Burger","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Keating","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Departments of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2019111807563918300_B1","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2007.15.7420","article-title":"Hairy cell leukemia: treatment successes in the past 25 years.","volume":"26","author":"Golomb","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111807563918300_B2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2008.19.6543","article-title":"The role of investigational therapy in management of patients with advanced metastatic malignancy.","volume":"27","author":"Freireich","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111807563918300_B3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","article-title":"Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.","volume":"322","author":"Piro","year":"1990","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111807563918300_B4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1200\/JCO.1989.7.2.168","article-title":"Pentostatin in the treatment of advanced hairy cell leukemia.","volume":"7","author":"Kraut","year":"1989","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111807563918300_B5","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"issue":"4","key":"2019111807563918300_B6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","article-title":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.","volume":"13","author":"Grever","year":"1995","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111807563918300_B7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.","volume":"145","author":"Else","year":"2009","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111807563918300_B8","first-page":"2981","article-title":"Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin.","volume":"96","author":"Flinn","year":"2000","journal-title":"Blood"},{"issue":"5","key":"2019111807563918300_B9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","article-title":"Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.","volume":"21","author":"Goodman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111807563918300_B10","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cncr.21447","article-title":"Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.","volume":"104","author":"Else","year":"2005","journal-title":"Cancer"},{"issue":"20","key":"2019111807563918300_B11","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1002\/cncr.25243","article-title":"Hairy cell leukemia: evaluation of the long-term outcome in 121 patients.","volume":"116","author":"Zinzani","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"2019111807563918300_B12","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1182\/blood.V87.4.1556.bloodjournal8741556","article-title":"Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine.","volume":"87","author":"Wheaton","year":"1996","journal-title":"Blood"},{"issue":"2","key":"2019111807563918300_B13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1309\/G6299513NGLCUB1K","article-title":"Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene.","volume":"119","author":"Sausville","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"2019111807563918300_B14","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1182\/blood-2005-11-4590","article-title":"Eradication of minimal residual disease in hairy cell leukemia.","volume":"107","author":"Ravandi","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111807563918300_B15","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-05-2315","article-title":"Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.","volume":"12","author":"Arons","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111807563918300_B16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2009-06-195370","article-title":"How I treat hairy cell leukemia.","volume":"115","author":"Grever","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111807563918300_B17","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2009-10-251645","article-title":"Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine.","volume":"115","author":"Sigal","year":"2010","journal-title":"Blood"},{"key":"2019111807563918300_B18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3109\/10428194.2011.565096","article-title":"Chemo-immunotherapy for hairy cell leukemia.","volume":"52","author":"Ravandi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2019111807563918300_B19","article-title":"Splenic B-cell lymphoma\/leukaemia, unclassifiable.","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Piris","year":"2008","edition":"4th ed"},{"issue":"12","key":"2019111807563918300_B20","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/modpathol.3880232","article-title":"PCR analysis of immunoglobulin heavy chain (IgH) and TcR-gamma chain gene rearrangements in the diagnosis of lymphoproliferative disorders: results of a study of 525 cases.","volume":"13","author":"Theriault","year":"2000","journal-title":"Mod Pathol"},{"issue":"2","key":"2019111807563918300_B21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0161-5890(92)90100-C","article-title":"Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire.","volume":"29","author":"Campbell","year":"1992","journal-title":"Mol Immunol"},{"issue":"6","key":"2019111807563918300_B22","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1182\/blood-2008-01-131987","article-title":"Soluble CD22 as a tumor marker for hairy cell leukemia.","volume":"112","author":"Matsushita","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111807563918300_B23","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma\u2013a randomized phase II trial of the Minnie Pearl Cancer Research Network.","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111807563918300_B24","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","article-title":"Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2019111807563918300_B25","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study.","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111807563918300_B26","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111807563918300_B27","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2009-03-212449","article-title":"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior.","volume":"114","author":"Forconi","year":"2009","journal-title":"Blood"},{"issue":"21","key":"2019111807563918300_B28","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood-2009-01-201731","article-title":"VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.","volume":"114","author":"Arons","year":"2009","journal-title":"Blood"},{"issue":"29","key":"2019111807563918300_B29","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia.","volume":"28","author":"Zenz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111807563918300_B30","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1182\/blood-2010-11-316737","article-title":"Evidence of canonical somatic hypermutation in hairy cell leukemia.","volume":"117","author":"Arons","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2019111807563918300_B31","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia.","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/14\/3818\/1316076\/zh804011003818.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/14\/3818\/1316076\/zh804011003818.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:10:44Z","timestamp":1574082644000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/14\/3818\/28709\/Phase-2-study-of-cladribine-followed-by-rituximab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,6]]},"references-count":31,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2011,10,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-04-351502","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,6]]}}}